CONGRESS FOR VOTERS

Michael Rulli (R-OH)

PEAT Act of 2026

H.R. 8630 · House bill Health

A Republican bill with 1 Democratic cosponsor · See all 12 cosponsors

Last activity — Referred to the House Committee on Energy and Commerce.

In committee

Introduced and handed to a committee in the chamber it started in.

The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.

Its path through Congress

  1. Introduced
  2. In Committee

What this bill would do

This bill, known as the "Protecting Equal Access to Thyroid Act of 2026" or the "PEAT Act of 2026," seeks to amend the Public Health Service Act. It specifically targets how biologics are classified. The bill proposes a prohibition on treating a biologic as a biological product based only on the presence of a protein that is a clinically inactive component. This change would alter the existing definitions within the Public Health Service Act.

Yes· 3 of 4

  • Scored +4

    Does this lower the price of prescription medicines?

    By preventing certain proteins from disqualifying products from being classified as biologics, the bill may facilitate the entry of more cost-effective treatments into the market.

  • Scored +3

    Does this make health care easier to get in general?

    The bill's reclassification of biologics could potentially lower barriers to accessing specific types of therapeutic products.

  • Scored +2

    Would households on low incomes be better off under this?

    Changes in biologic classification may eventually lead to lower costs for essential medications used by low-income populations.

The opposite

No question was scored the opposite.